



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Summary of Main Points from the Meeting held on Monday 14th May 2018

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the 9th April 2018 Medicines Group meeting were approved and will be circulated.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

- **Netupitant 300mg / Palonosetron 0.5mg Capsules (Akynzeo[®])**

Requested by the Oncology Team for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy. This will be administered as a single prior to chemotherapy and will replace the current anti-emetic regimen which includes giving 5 individual anti-emetic agents. There will be a total cost saving of £15.22 per patient including the time spent prescribing, administering and/or dispensing the 5 individual anti-emetics agents.

Decision: Approved for addition to the formulary

Ex-panel

- **Testosterone (Testogel) 16.2mg/g Pump**

Added to NWLIF in April 2018. There is a long-term manufacturing issue with Testogel 50mg/5g sachets. The company (Besins) that produce the sachets are recommending their new product, Testogel 16.2mg/g pump. The pump provides comparable dosing to the sachets. Minimal price difference between the two formulations.

Decision: Approved for addition to the formulary

Removals

- **Liothyronine 20mcg Tablets**

Proposal to remove from the formulary following the publication of the NHS England Consultation re. Items which should not routinely be prescribed in Primary Care

Decision: Approved for removal from the formulary

- **Ulipristal 5mg Tablets**

MHRA have reported five cases of serious liver injury, including four cases of hepatic failure needing liver transplantation, worldwide in women using Esmya for uterine fibroids.

Advice: Do not initiate new treatment courses of Esmya, including in women who have completed one or more treatment courses previously.

Removed from NWLIF in April 2018.

Proposal to remove Ulipristal 5mg tablets from the formulary.

Decision: Approved for removal from the formulary

- **Ciprofibrate 100mg Tablets**

CCG initiation to switch programme to switch from using ciprofibrate to either fenofibrate or bezafibrate given the significant cost differences.

Currently there is very low usage at both hospital sites.

Proposal to remove Ciprofibrate 100mg Tablets these from the formulary.

Decision: Approved for removal from the formulary

- **Dithranol 3% Cream (Micanol[®])**

Discontinued by manufacturer

Proposal to remove Dithranol 3% Cream (Micanol[®]) from the formulary.



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Decision: Approved for removal from the formulary

- **Cerner Project - Formulary change requests**

Cerner has highlighted a number of drugs that have been discontinued by the manufacturers. In addition a number of drugs have been identified that have very low usage. Proposal to remove these from the formulary.

Decision: Approved for removal from the formulary

NICE Approved drug applications

- **TA499 - Glecaprevir–pibrentasvir for treating chronic Hepatitis C**

Application form for drug approved by NICE.

Decision: Approved for addition to the formulary

- **TA507 - Sofosbuvir–velpatasvir–voxilaprevir for treating chronic Hepatitis C**

Application form for drug approved by NICE.

Decision: Approved for addition to the formulary

- **TA510 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma**

Application form for drug approved by NICE.

Decision: Approved for addition to the formulary

- **TA511 - Brodalumab for treating moderate to severe plaque psoriasis**

Application form for drug approved by NICE.

Decision: Approved for addition to the formulary

- **TA513 - Obinutuzumab for untreated advanced follicular lymphoma**

Application form for drug approved by NICE.

Decision: Approved for addition to the formulary

Pharmacoeconomic Board requests

- **Clonidine patches for Dystonia**

Approved by the Pharmacoeconomic Board for a complex paediatric patient with Dystonia on 06/04/2018.

Decision: Noted

4.2 Trust Medicines Policy

- **TMP - Section 21: Non-Medical Prescribing**

Updated in light of the change in Trust Non-Medical Prescribing Lead - Gillian Avery

Decision: Approved

- **TMP - Section 30: Supply of Over-labelled/Pre-packed medicines by Nurses/Midwives on Wards/Departments**

Updated to include the addition of Lord Wigram Ward as a clinical area that can work under this policy.

Decision: Approved

- **Trust Paediatric and Neonatal Administration Guide - Updates**

Updates:

- Listed minor changes



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

- New Monograph for Magnesium Sulphate IV

Decision: Approved

4.3 Medicines Optimisation

• **Contrast Media Vial Sharing - Risk Assessments**

Risk Assessments to support vial sharing for the following three Contrast Media agents:

- Visipaque
- Omnipaque
- SonoVue

Localised cost analysis if vial sharing was undertaken at both sites for these three agents:

	CWH	WMUH
Visipaque	N/A	£10k combined for both agents
Omnipaque	N/A	
SonoVue	£7,644	£45,000

Two devices that are proposed to be used for vial sharing of the three contrast media agents were presented. It was explained that the two devices are specially designed to ensure that the aliquots of liquid being removed from the vial for each patient do not mix with the primary liquid in the vial therefor eliminating any risk of transfer of contamination from one patient to another.

Decision: Approved for use within the Trust in this specified speciality only.

Action: Risk assessment to be forwarded for inclusion on the Trust Risk Register.

• **NHS England: Conditions for which over the counter items should not routinely be prescribed in primary care: Guidance for CCGs**

Final published guidance from NHS England re. Conditions for which over the counter items should not routinely be prescribed in primary care.

Decision: Noted

• **Implementation of FreeStyle Libre[®] continuous glucose monitoring system**

Plan for implementation of FreeStyle Libre[®] continuous glucose monitoring system across NHS in London
Enclosed:

- NHS London Guidance - Full
- NHS London Guidance - Summary
- Information on training
- Trust Memo sent to the Diabetes Teams at both sites ahead of launch

Decision: Noted

• **Cerner option Appraisals (Formulary and Drug-Drug interactions)**

Options Appraisals for the management of the following on Cerner:

- Formulary
- Drug-Drug interactions

Decision: Noted



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

4.4 NICE Technical Appraisals and Guidance

NICE Technical Appraisals

a) 5 Appraisals were published in April 2018

TA515 - Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen

Formulary status / Action

N/A - Not recommended

TA516 - Cabozantinib for treating medullary thyroid cancer

Formulary status / Action

Nil action - Not applicable to CWH

TA517 - Avelumab for treating metastatic Merkel cell carcinoma

Formulary status / Action

For addition to the formulary following receipt of a signed application form from Dr Brock

TA518 - Tocilizumab for treating giant cell arteritis

Formulary status / Action

Likely to be commissioned at Specialist Centres only. Currently confirming if CWH will be regarded as a Specialist Centre.

TA519 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

Formulary status / Action

Currently included on the formulary. Numbers likely to treat at CWH site: 3-4 patients per year.

b) NICE Technology Appraisals Adherence Table 2017-18

Adherence status for all NICE TA published from April 2017 to March 2018.

Decision: Approved for publication on the Trust Internet website.

4.5 IVIG Update

- **IVIG requests**

April 2018

CWH Site

There were 18 IVIG issues, with 7 new requests

WMUH Site

To be reported at June meeting

Decision: Approved

4.6 Items for noting

- **Quarterly Q4 2017/18 Controlled Drug Summary Report**

Quarterly Controlled Drug Summary Report for Q4 2017/18

Decision: Noted

- **Quarterly Q4 2017/18 Controlled Drugs Accountable Officer Report**



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Quarterly Controlled Drugs Accountable Officer for Q4 2017/18

Decision: Noted

- **TMG Log of Attendance 2017-18 and 2018-19**

Log of attendance at TMG for Dec 2017, Feb 2018 and March 2018

Log of attendance at TMG for Dec 2017, Feb 2018 and April 2018

Decision: Noted

- **Trust Medication Safety Group: Terms of Reference**

Reviewed and updated Terms of Reference for the Medication Safety Group:

Comprehensive update regarding Objectives,

- Updated aims and objectives
- New accountability including key relationships
- New method of working
- Updated frequency of meeting
- Updated quorum requirements
- Updated membership details
- New roles and responsibilities of members
- New openness
- Review date clearly defined and included in body of text
- New approval group included in body of text

Decision: Noted

- **MHRA Drug Safety Update - April 2018**

MHRA update for March 2018

Decision: Noted

4.7 Meeting minutes for noting

- **Medication Safety Group Meeting - March 2018**

Minutes from Medication Safety Group Meeting - March 2018

Decision: Noted

- **Chemotherapy Service Group (CSG) - March 2018**

Minutes from Chemotherapy Service Group (CSG) - March 2018

Decision: Noted

4.8 Additional papers to go to Trust patient Safety Group

- Quarterly Q4 2017/18 Controlled Drug Summary Report
- Quarterly Q4 2017/18 Controlled Drugs Accountable Officer Report

5. Any other business

Nil

6. Date of next meeting

Date: Monday 11th June 2018

Time: 8am-9am

Location: Board Room (CWH Site) and Meeting Room A (WMUH Site via video conferencing)

Closing date: 18th May 2018